Related Experiment Videos
Interferon therapy in the chronic aggressive viral hepatitis
1Clinic of Internal Medicine, Fundeni Hospital, Bucharest, Romania.
Medecine Interne
|July 1, 1990
Summary
Interferon (INT) alpha therapy effectively treats chronic aggressive hepatitis of viral origin (CAVH) by inhibiting viral replication. Treatment outcomes depend on various factors including dose, duration, and patient characteristics.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic aggressive hepatitis of viral origin (CAVH) progresses due to persistent viral replication in immunocompromised hosts.
- Interferon (INT) exhibits antiviral, immunomodulating, and antitumoral properties beneficial for treating viral hepatitis.
Purpose of the Study:
- To critically review the efficacy of interferon (INT) therapy for chronic aggressive hepatitis of viral origin (CAVH).
- To analyze the effectiveness of INT alpha class in CAVH treatment based on recent clinical trials.
Main Methods:
- Comprehensive review of clinical trials investigating interferon alpha in CAVH.
- Analysis of factors influencing therapeutic response and recurrence risk.
Main Results:
- Interferon (INT) alpha is identified as the most suitable class for CAVH treatment.
- Clinical trials demonstrate significant effectiveness of INT alpha in CAVH across different hepatitis viruses.
Conclusions:
- Interferon (INT) alpha therapy is a proven treatment for chronic aggressive hepatitis of viral origin (CAVH).
- Therapeutic response and recurrence are influenced by treatment parameters and patient-specific factors.